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Abstract
The second-generation antipsychotic olanzapine is effective in reducing psychotic
symptoms but can cause extreme weight gain in human patients. We investigated
the role of the gut microbiota in this adverse drug effect using a mouse model. First,
we used germ-free C57BL/6J mice to demonstrate that gut bacteria are necessary
and sufficient for weight gain caused by oral delivery of olanzapine. Second, we
surveyed fecal microbiota before, during, and after treatment and found that
olanzapine potentiated a shift towards an ‘‘obesogenic’’ bacterial profile. Finally, we
demonstrated that olanzapine has antimicrobial activity in vitro against resident
enteric bacterial strains. These results collectively provide strong evidence for a
mechanism underlying olanzapine-induced weight gain in mouse and a hypothesis
for clinical translation in human patients.
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Introduction
The second-generation (‘‘atypical’’) antipsychotic drug olanzapine is commonly
prescribed as a first-line treatment for schizophrenia, bipolar disorder, and other
psychotic disorders. Since their introduction in the 1990s, olanzapine and other
atypical antipsychotics have come into widespread clinical use because they are
efficacious and usually lack the extrapyramidal adverse drug reactions associated
with older, ‘‘typical’’ antipsychotics like haloperidol [1, 2]. However, atypical
antipsychotics can induce dramatic weight gain: 11–17 kg in a systematic review
of treatment-naïve adults [3] and 7–9 kg in adolescents over short-term treatment
[4]. Olanzapine in particular is associated with a deterioration of metabolic
parameters and development of a syndrome resembling type 2 diabetes [3–6].
Individuals with schizophrenia are less physically healthy than the general
population, with life expectancy reduced by as much as 25 years [3, 7–9].
Cardiovascular disease is a leading cause of death in schizophrenia [3, 9]: tobacco
use, poor diet, and socioeconomic disparities conspire to create a profoundly
unfavorable cardiovascular risk profile that is compounded by weight gain and the
metabolic side effects of antipsychotic drugs. Understanding the mechanisms [10–
13] of these adverse drug reactions and developing mitigating strategies are of
considerable clinical importance [14].
The role of the commensal microbiome of the mammalian gut in health and
disease has become a topic of intense study. Bacterial concentrations can be as
high as 1011 cells/mL in the distal gut, encompassing a gene repertoire 150 times
larger than that of the human host [15] with broad-ranging metabolic capacity
[16, 17]. Millions of years of coevolution have shaped the metabolic capacity of
the gut microbiome and its human host [18]. Recent studies in animal models
and humans have demonstrated a causal role for the gut microbiome in obesity
[19–24], which is mediated by complex interactions with host environment
[25, 26], diet [21, 27] and genetics [25, 28].
Since olanzapine is usually administered orally and approximately 30% of the
dose enters the enterohepatic circulation [29], the gut microbiome represents a
plausible mechanistic link and potential therapeutic target for olanzapine-induced
metabolic dysfunction. After establishing that C57BL/6J mice gain considerable
weight while consuming olanzapine, we demonstrated that: (a) germ-free mice do
not gain excess weight on olanzapine, (b) the same germ-free mice gain excess
weight on olanzapine following introduction of cecal microbiota, (c) olanzapine
induces a shift to an obesogenic gut bacterial profile, and (d) olanzapine has
modest intrinsic antimicrobial activity. Our results are broadly consistent with
those recently obtained in outbred rats [30, 31] but offer a more precise
characterization of inter-individual variability against a defined genetic back-
ground.
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Materials and Methods
Olanzapine administration
Olanzapine was compounded into high fat (45 kcal%) food (diet D09092903) at a
concentration of 50 mg/kg of diet by Research Diets, Inc (New Brunswick, NJ).
This dose was selected following a four-week dose-ranging study in C57BL/6J
mice (0, 12.5, 25, 50, 100 mg/kg), since it produced steady-state plasma levels
(21¡5 ng/ml) closest to the clinically relevant range (10–50 ng/mL; see S2 Figure
and [32]). Plasma olanzapine levels were measured using the liquid chromato-
graphy/tandem mass spectrometry (LC-MS/MS) method of Zhang et al. [33].
Placebo-treated animals received the same high fat diet (D09092903), minus
olanzapine, prepared in parallel to control for batch effects.
Strain survey
For the strain survey (Fig. 1A), n58 female mice (aged 6 weeks) from each of
eight inbred strains (A/J, C57BL/6J, 129S1SvlmJ, NOD/ShiLtJ, NZO/HlLtJ, CAST/
EiJ, PWK/PhJ, WSB/EiJ) were acquired from the Jackson Laboratory (Bar Harbor,
ME). All mice were maintained on standard chow (Purina Prolab RMH3000,
14 kcal% fat) until 8 weeks of age and then switched to high fat diet ¡ olanzapine
for 10 weeks. There was one cage of olanzapine-treated mice (n54) and one cage
of placebo-treated mice (n54) for each strain. Animals were maintained on a 14-
hour light, 10-hour dark schedule with lights on at 0600. The housing room was
maintained at 20–24 C̊ with 40–50% relative humidity. Mice were group-housed
(4 per cage) in standard 20 cm630 cm ventilated polysulfone cages with
laboratory grade Bed-O-Cob bedding. Water and feed were available ad libitum
throughout the experiment.
Germ-free study
Germ-free experiments were performed in the National Gnotobiotic Rodent
Resource Center at the University of North Carolina. Twenty-four female C57BL/
6J mice were born in a germ-free isolator and randomized to 6 cages (4 per cage.)
At 6 weeks of age, 3 cages were randomized to receive olanzapine and 3 cages to
receive placebo (n512 mice per group; Fig. 1B). Olanzapine was administered in
feed as detailed above, except that both drug and placebo feed was doubly
irradiated prior to import into the germ-free isolator. Germ-free status was
confirmed by biweekly monitoring for the presence of bacteria in the feces by
aerobic and anaerobic culture as well as Gram staining of the stool. After 7 weeks
of treatment, mice were moved to conventional housing (maintaining the same
cage assignments) at which time each mouse was gavaged with 200 caecal slurry
(500 uL caecal contents form a single conventionally-raised C57BL/6J female
diluted 1:10 in sterile PBS)[34]. Following gavage, all mice were maintained on
drug-free high-fat diet for 2 weeks in order to allow colonization of the gut
without interference from olanzapine. After the 2 week colonization period,
treatment was resumed in the olanzapine group for another 7 weeks.
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Fig. 1. Experimental design. (A) Eight groups of 8 female mice representing the founder strains of the Collaborative Cross project (A/J, C57BL/6J,
129S1SvlmJ, NOD/ShiLtJ, NZO/HlLtJ, CAST/EiJ, PWK/PhJ, WSB/EiJ) were received from the Jackson Laboratory at 6 weeks of age. Within each strain,
mice were randomized to receive either olanzapine (OLZ, 50 mg/kg diet) or placebo while consuming a high-fat diet (HFD) ad libitum beginning at 8 weeks
of age. Body weight was measured at time points indicated by grey dots; adiposity was measured by magnetic resonance imaging (MRI) at time points
indicated by purple dots. (B) Six cages of 4 female C57BL/6J mice were reared in germ-free (axenic) conditions. At 6 weeks of age, each cage was
randomized to either HFD alone (3 cages; n512) or HFD plus OLZ (3 cages; n512). After 7 weeks of treatment mice were inoculated by oral gavage
followed by a 2-week drug-free colonization period. Treatment was resumed for an additional 7 weeks under conventional housing conditions. (C) Two
groups of 12 female C57BL/6J mice were received from the Jackson Laboratory at 4 weeks of age and randomized to study arms (group A or B). Both
groups were acclimated to the facility for 2 weeks, during which time they were fed regular mouse chow, then both groups were switched to HFD for 1 week.
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Crossover study
For the crossover study (Fig. 1C), n524 female C57BL/6J mice (aged 4 weeks)
were acquired from the Jackson Laboratory. Upon arrival in the facility, animals
were randomly assigned to cages (4 mice per cage), and cages randomized to study
arms (group A or group A; 3 cages per group). Both groups were fed standard
chow from 4–6 weeks of age, then both groups were switched to high-fat diet for 1
week. For weeks 8–11, group A received placebo and group B received olanzapine.
During weeks 12–15, groups were swapped so that group A received olanzapine
and group B received no drug. All mice received the high-fat diet from week 7 to
the conclusion of the study.
Collection of metabolic phenotypes
Body weight (¡0.1 g) was measured weekly for the strain survey, biweekly in the
germ-free isolator, and biweekly for the crossover study, always between the hours
of 0800–1000. Body composition (fat, lean, and water mass ¡0.01 g) was
measured in un-anaesthetized mice using a quantitative magnetic resonance body
composition analyzer [35] (EchoMRI, Houston, TX, USA). Adiposity (% body
fat) was calculated as 1006 (fat weight)/(total body weight).
Ethics statement
This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. The protocols were approved by the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill (protocol numbers:
11–318.0, 11–320.0).
Bacterial growth-inhibition assays
Escherichia coli NC101 and Enterococcus fecalis OGIRF were grown shaking
overnight at 37 C̊ in brain heart infusion (BHI) broth supplemented with 1%
IsoVitalex (Becton-Dickson). Overnight cultures were resuspended in phosphate-
buffered saline (PBS) to a Klett reading of 100 (approximately 16109 CFU/ml).
Resuspended cultures were diluted 1:20 in a 96 well plate with a range of
olanzapine concentrations (0–580 mg ml21). Olanzapine is insoluble in BHI so
DMSO was added and used as a control (17.5% of the culture volume). Growth
curves were performed at 37 C̊ while shaking in an Infinite M200 (Tecan)
apparatus in 96-well microtiter plates with absorbance (optical density at 600 nm,
OD600) monitored every 15 min. Minimal inhibitory concentrations were
For weeks 8–11, group A was maintained on high-fat diet and group B was switched to HFD plus OLZ. For weeks 12–15, groups were swapped so that
group A received OLZ and group B received no drug. Body weight and adiposity phenotypes were collected at the indicated time points. Fecal pellets were
collected for microbiome profiling at time points indicated by orange dots.
doi:10.1371/journal.pone.0115225.g001
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determined by identifying the lowest concentration of olanzapine that inhibited
growth and did not exceed an OD600 of 0.2.
Gut microbiome sampling
Fecal samples were collected from the 24 mice in the crossover at 4 different time
points (Fig. 1C, a total of 96 samples), in order to follow individual changes in the
microbiome resulting from diet and drug treatment. Fresh fecal pellets were
collected by transferring an individual mouse to a clean cage for 5 minutes,
collecting 3–5 pellets into a microcentrifuge tube with sterile forceps, snap
freezing on dry ice and storing at 280 C̊. Bacterial DNA was extracted using a
PowerSoil 96-well DNA isolation kit (MO BIO Laboratories, Inc; Carlsbad, CA)
on an automated pipetting system (epMotion 5075; Eppendorf AG; Hamburg,
Germany).
Hypervariable region 4 (V4) of the 16S ribosomal RNA subunit gene was
amplified by the molecule-tagged PCR method [36] Briefly, this technique adds a
unique oligonucleotide sequence (the ‘‘molecular tag’’) to each template molecule
in the first round of amplification so that PCR artifacts are readily identified and
corrected in downstream analyses. A 96-plex barcoded library was prepared using
the Illumina Nextera chemistry (Illumina Inc; San Diego, CA). Samples were
randomly allocated to barcodes. The library was sequenced in a single 26250 bp
paired-end run on the Illumina MiSeq platform. Standard preprocessing and
demultiplexing of sequence reads was performed using the CASAVA v1.8.2
software from Illumina. Library preparation, sequencing and preprocessing were
performed by staff at the University of North Carolina High-Throughput
Sequencing Facility. Raw sequence reads have been deposited in the NCBI Short
Read Archiveunder BioProject PRJNA264871.
Sequence reads were processed using the MT_MTToobox software of Lundberg
et al. (https://sites.google.com/site/moleculetagtoolbox). This pipeline merges raw
reads into consensus sequences representing a single template (via its molecular
tag), thus detecting and removing PCR chimeras and amplification artifacts;
counts read abundance within each consensus group; and bins consensus
sequences into operational taxonomic units (OTUs) at a 97% sequence similarity
threshold. OTUs were assigned a taxonomic identity with the RDP classifier [37]
trained on the most recent release (4 February 2011) of the Los Alamos National
Laboratory’s GreenGenes taxonomic reference (gg_97_otus_4feb2011), using the
scripts in the QIIME v1.5.0 package [38]. Consensus sequences for the OTUs were
aligned using PyNAST [39] (via QIIME) guided by the aforementioned
GreenGenes reference alignment, and a corresponding phylogeny inferred using
FastTree [40] (via QIIME). Between-samples (b) diversity indices were calculated
using UniFrac [41] (via QIIME) after rarefying all samples to 6997 unique
template sequences. The final UniFrac distance matrices represent the average
over 10 000 rarefactions.
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Statistical analysis
In order to account for the several levels of correlation present in this experiment,
we analyzed changes in body weight, adiposity and microbial parameters using
generalized linear mixed models (GLMMs) as implemented in the R package lme4
(http://lme4.r-forge.r-project.org). Between-group differences in overall micro-
biota composition were assessed by PERMANOVA [42] as implemented in the R
package vegan (http://vegan.r-forge.r-project.org), and visualized using non-
metric multidimensional scaling as implemented in the R package MASS [43].
Further details regarding statistical methods are provided in S1 Notes.
Results
Olanzapine potentiates weight gain on high-fat diet
To develop a model for olanzapine-induced weight gain in mouse, we surveyed
eight inbred strains (A/J, C57BL/6J, 129S1SvlmJ, NOD/ShiLtJ, NZO/HlLtJ, CAST/
EiJ, PWK/PhJ, WSB/EiJ) which are the founder strains of the Collaborative Cross
population [44]. Eight females from each strain were randomized to receive either
olanzapine (compounded into feed at 50 mg/kg) or placebo and were fed a high-
fat diet ad libitum (Fig. 1A). The rate of weight gain and the effect of olanzapine
were highly variable between strains (S1A Figure). Plasma olanzapine levels were
measured after 18 weeks of treatment (S1B Figure). C57BL/6J mice were highly
susceptible to olanzapine-induced weight gain, gaining a mean of 17.1% over
Fig. 2. Effect of high-fat diet plus olanzapine (OLZ; filled circles) versus placebo (PLA; open circles) on
body weight in germ-free mice. Points in the left-hand third represent observations under germ-free
conditions. The first dashed line marks the beginning of the drug-free conventionalization period (with
colonization by gavage) and the second dashed line marks the resumption of treatment under conventional
conditions. Each point represents the mean across 12 mice; error bars are ¡ 2 standard error.
doi:10.1371/journal.pone.0115225.g002
An Antipsychotic Drug Interacts with Gut Microbiome
PLOS ONE | DOI:10.1371/journal.pone.0115225 December 15, 2014 7 / 20
initial body weight (95% CI 13.6–20.6%, p51.0661025) and were therefore
selected for further study. A dose-response study was conducted in C57BL/6J mice
order to titrate drug dosage to a clinically-relevant level (S2 Figure). The plasma
concentration in which olanzapine has the greatest effect on body weight and
adiposity (10–25 ng/mL) corresponds with the therapeutic range in human
patients [32].
Gut microbiota is necessary and sufficient for olanzapine-induced
weight gain
To investigate the role of the gut microbiota in olanzapine-induced weight gain,
24 female C57BL/6J mice were raised in germ-free conditions (Fig. 1B). At 6
weeks of age, 12 mice were randomized to high-fat diet plus olanzapine (50 mg/
kg) and 12 to high fat diet alone. After 7 weeks of treatment in germ-free
conditions, no significant difference in body weight was observed between groups
(Fig. 2; 95% CI for difference 20.75–1.61 grams; p50.478). Under conventional
conditions in the strain survey (S1A Figure), olanzapine-treated C57BL/6J females
had gained 4.6 grams more than untreated mice (95% CI for difference 1.67–7.48
grams; p58.8161023) during the first 7 weeks of treatment. Mice were then
transferred to conventional housing and gavaged with a slurry of cecal contents
from a female C57BL/6J donor mouse. Following a 2-week acclimation period,
treatment was resumed for another 7 weeks, during which the olanzapine group
gained significantly more weight than placebo group (Fig. 2; 95% CI for
difference 1.33–5.75 grams; p54.961023). These results demonstrate that gut
microbiota are both necessary and sufficient for weight gain induced by
olanzapine in the context of a high-fat diet.
Interrogating the gut microbiota and weight using a crossover
design
To study the effects of olanzapine on the gut microbiome, 24 six-week-old female
C57BL/6J mice raised on regular mouse chow in conventional conditions
consumed a high-fat diet for 2 weeks, and then randomized to receive either 4
weeks of high-fat diet plus placebo (group A) or 4 weeks of high-fat diet plus
olanzapine (group B). After 4 weeks the treatments were switched. Total body
weight and adiposity were measured periodically throughout (Fig. 1C). Weight
gain during the olanzapine phase (shaded interval in S3A Figure) was more rapid
than during the placebo phase (95% CI 2.9–10.9% increase over initial weight,
p52.8061027). The effects of olanzapine were variable between mice (S4 Figure).
Adiposity (fat mass as a percentage of total body weight, assessed by whole body
MRI) also increased markedly during the olanzapine phase (S3B Figure) and was
highly correlated with total body weight (S3C Figure; Pearson’s r50.894, 95% CI
0.836–0.933). Olanzapine was associated with increased adiposity even after
accounting for weight gain (95% CI 1.4–4.5%, p54.4661024).
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Fecal pellets were collected from each mouse before, during and after initiation
of the high-fat diet and olanzapine treatment (4 temporally-matched samples per
mouse, Fig. 1C). Gut microbiota were surveyed by high-throughput sequencing
of the bacterial 16S ribosomal RNA gene, a widely-used marker gene in microbial
ecology. The resulting sequences were clustered into a total of 8067 operational
taxonomic units (OTUs) and were identified and classified at the family level, of
which a median of 612 were present per individual sample. Further details of the
Fig. 3. Effect of high-fat diet (HFD) and olanzapine (OLZ) treatment on diversity of gut microbiota during crossover study. (A) Within-subject (a)
diversity, quantified by Fisher’s a [45]; larger values indicate greater diversity (n595 samples 54 time points 624 subjects – 1 failed sample). Panels are
split by study arm (see Error! Reference source not found.) and points are colored according to diet and treatment status: on regular chow prior to initiation
of HFD (regular), during treatment with placebo (HFD-placebo) or during treatment with OLZ (HFD-OLZ). Each point represents a single individual and bars
indicate 95% confidence intervals about the point estimates; observations on the same subject are connected by a grey line. (B) Between-subjects (b)
diversity (n595 samples 54 time points624 subjects – 1 failed sample). Pairwise distances between samples were calculated using weighted UniFrac and
visualized using non-metric multidimensional scaling along two axes, which together explain 98% of between-subjects variance. Observations on the same
subject are connected by a grey line.
doi:10.1371/journal.pone.0115225.g003
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Table 1. PERMANOVA decomposition of b-diversity as measured by UniFrac.
Term df SS‘ F# R2 p-value
Weighted UniFrac cage 5 0.3537 3.843 0.0728 0.0004
diet 1 2.2813 123.94 0.46954 ,1.0061024
time point 2 0.5435 14.762 0.11185 ,1.0061024
drug 1 0.1156 6.278 0.02378 0.0028
Residuals 85 1.5646 0.32202
Total 94 4.8586
Unweighted UniFrac cage 5 1.279 1.944 0.07742 ,1.0061024
diet 1 2.7293 20.7412 0.16519 ,1.0061024
time point 2 1.096 4.1644 0.06634 ,1.0061024
drug 1 0.2325 1.767 0.01407 0.021
Residuals 85 11.1849 0.67698
Total 94 16.5217
*df, degrees of freedom; ‘SS, Sum of squares; #F, pseudo-F-statistic.
doi:10.1371/journal.pone.0115225.t001
Fig. 4. Compositional shifts in gut microbiota induced by high-fat diet (HFD) and olanzapine (OLZ) during crossover study. (A) Colored blocks show
relative abundance of specific bacterial classes during treatment with OLZ (HFD-OLZ) or placebo (HFD-placebo), pooled across individuals in each of the
two study arms (n53 time points 624 subjects). (B) Effect of OLZ on relative abundance of specific taxa, expressed as confidence intervals (at nominal
significance level a50.05) about the mean fold-change in relative abundance. Taxa with a statistically-significant increase are shown in red, and those with a
significant decrease in blue. (C) Effect of relative abundance of specific taxa on weight gain, expressed as confidence intervals (at nominal significance level
a50.05) about the effect estimate.
doi:10.1371/journal.pone.0115225.g004
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sequencing protocol, analysis, and bioinformatics are provided in supplementary
material.
Olanzapine and high-fat diet act synergistically on gut microbiota
The switch to high-fat diet was associated with a modest increase in within-sample
microbial diversity (a-diversity) after adjusting for temporal and co-housing
effects (Fisher’s a [45], 95% CI 23.5–43.1 additional units, p54.0261028), but
this effect varied between mice (Fig. 3A). Olanzapine treatment decreased a-
diversity, but the effect was not significant after adjusting for temporal and co-
housing effects (p50.449).
Between-samples (b) diversity was measured by weighted and unweighted
UniFrac metrics, complementary phylogenetically-scaled multivariate distance
metrics [41]. In the weighted UniFrac analysis (Fig. 3B, which is sensitive to the
presence/absence of OTUs and differences in abundance between samples, the
high-fat diet effect accounts for 46.9% of variance (permutation p,1.0061024;
Table 1), while the olanzapine treatment effect explains 2.4% (permutation
p50.0028). Within-groups dispersion was not different in the regular chow vs.
high-fat diet or high-fat diet-placebo vs. high-fat diet-olanzapine comparisons.
Unweighted UniFrac results are presented in S5 Figure and discussed in
supplementary material.
Fig. 5. Effect of olanzapine (OLZ) on growth of Escherichia coli NC101 and Enteroccoccus faecalis
OGIRF in vitro. Bacterial growth is measured as optical density at 600 nm wavelength. Measurements of
growth in rich medium (brain heart infusion, BHI) plus vehicle (dimethylsulfoxide) only is included as a control.
Each line represents the mean of three independent experiments.
doi:10.1371/journal.pone.0115225.g005
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Gut microbiota composition for mice treated with olanzapine or placebo while
receiving a high-fat diet is presented in Fig. 4A (in aggregate) and S6 Figure (per
individual). Olanzapine treatment induced an increase in the relative abundance
of members of class Erysipelotrichi from phylum Firmicutes (95% CI 1.7–3.4%,
adjusted p52.6361026) and class Gammaproteobacteria from phylum
Proteobacteria (95% CI 0.079–0.45%, adjusted p53.1161022), and a decrease in
class Bacteroidia from phylum Bacteroidetes (95% CI 25.3–21.2%, adjusted
p52.0661022) (Fig. 4B). This pattern has previously been associated with
obesity in mouse and human [19, 24].
Gut microbiota composition is correlated with weight gain
Relationship between relative abundance of specific bacterial taxa and weight gain
during olanzapine treatment was assessed using linear mixed-effects models
(Fig. 4C). The relative abundance of members of class Erysipelotrichi increased
with olanzapine treatment and was associated with more rapid weight gain (0.71%
increase in weight per 1% increase in abundance, 95% CI 0.33–1.10,
p55.4561023). Class Actinobacteria, for which a drug effect was not noted, was
also associated with weight gain (4.9% increase in weight per 1% increase in
abundance, 95% CI 2.3–7.7, p55.4461023).
Olanzapine has direct and specific antimicrobial action in vitro
We tested the effects of olanzapine on growth of two commensal enteric bacterial
strains (Escherichia coli NC101 and Enterococcus faecalis OGIRF) across a range of
supraphysiologic concentrations (280 mg/mL to 560 mg/mL) in vitro. These two
strains were chosen because they represent highly abundant species from two of
the dominant phyla (E. coli: Proteobacteria; E. faecalis: Firmicutes) of the
mammalian gut. Susceptibility to olanzapine differs between the two species as
shown in Fig. 5. Growth of E. coli is completely inhibited by 537 mg/ml
olanzapine, while growth of E. faecalis shows a delay in reaching log-phase growth
but not complete growth arrest.
Discussion
We have demonstrated that the antipsychotic olanzapine, when administered at a
clinically-relevant dose, accelerates weight gain resulting from high-fat diet in
C57BL/6J mice. This effect is absent under germ-free conditions but emerges
quickly upon microbial colonization of the gut. Gut microorganisms are therefore
necessary and sufficient for a common adverse effect of this highly-prescribed
antipsychotic. Using a randomized crossover study design that accounts for inter-
individual variation in the gut microbiota, we have shown that olanzapine induces
subtle changes in the composition of the gut microbiota beyond the effect of a
high-fat diet alone. Importantly, these alterations are qualitatively similar to the
effect of a high-fat diet alone, and are quantitatively correlated with degree of
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weight gain. Finally and surprisingly, we find that olanzapine has antibiotic
activity for two common resident bacterial species in vitro. To our knowledge,
these results provide the first description of an adverse drug effect mediated by the
commensal microbiome.
Weight gain was initially measured in the eight inbred mouse strains that are
the founders of the Collaborative Cross [44, 46]. Consistent with observations in
human studies, the survey revealed variation in both magnitude and reprodu-
cibility of olanzapine-induced weight gain between strains during high-fat feeding,
independent of steady-state drug concentrations. This indicates that susceptibility
to weight gain has a genetic component amenable to dissection via the
Collaborative Cross or its sister resource, the Diversity Outbred stock [47].
The composition of the gut microbiota has been shown to be heritable and
genetically complex [28]. In contrast to previous experiments in outbred rats
[11, 30, 31], we studied isogenic mice. The degree of inter-individual variability
observed in changes to the gut microbiota is therefore striking (Fig. 3, S6 Figure).
A portion of this variability is probably technical artifact, [48] but true stochastic
effects almost certainly make important additional contributions [49], which we
detect as temporal and cage effects (Table 1). The large bloom in
Verrucomicrobiae in three cages at the fourth fecal-sampling time point (S6
Figure) may be an example and is consistent with observations that the
microbiota of co-housed mice tend to converge over time [25, 49]. Finally, the
maternal microbiota and the post-weaning environment can influence the
composition of the gut microbiota during the initial period of colonization [50].
Although we do not directly control for maternal effects, our use of careful
randomization of mice to cages and to study arms minimized confounding due to
early-life exposures.
The specific alterations in gut community composition that we attribute to
olanzapine are similar to those attributed to high-fat diet [19, 21, 22, 30, 31]. This
is immediately evident from the NMDS plot in Fig. 3: observations during
placebo and olanzapine treatment phases vary along the same dimension as
observations during feeding with regular chow and observations during high-fat
feeding, although the effect of diet appears to predominate. That the effect sizes
for both high-fat diet (46.9% vs. 16.5% variance explained) and olanzapine (2.4%
vs. 1.4%) are greater in the weighted than unweighted UniFrac analyses (Table 1)
suggests that drug- and diet-induced alterations in community structure are more
quantitative than qualitative. Relative abundance of class Erysipelotrichi (phylum
Firmicutes) and class Gammaproteobacteria (phylum Proteobacteria) increased
during olanzapine treatment, while relative abundance of members of class
Bacteroidia (phylum Bacteroidetes) decreased. An identical pattern has previously
been associated with the switch from low-fat chow to a high-fat ‘‘Western diet’’ in
mice with humanized gut microbiota [22]. Both Erysipelotrichi and
Gammaproteobacteria have been associated with non-alcoholic fatty liver disease
independently of weight gain in human [51, 52] and mouse [53]. Class
Bacteroidia, decreased during olanzapine treatment in the present experiment and
negatively (though not significantly) correlated with weight gain, has been shown
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to be enriched in lean members of twin pairs discordant for obesity, and its
leanness-promoting effects were transmissible [24]. Collectively these associations
indicate that olanzapine induces a shift towards a microbiota that has been
demonstrated in both mouse and human to promote weight gain. However, we
note that the composition of gut bacterial communities is an imperfect proxy for
their metabolic capacity [50]; further studies will be required to elucidate
functional consequences of olanzapine treatment.
Finally we demonstrate that olanzapine has direct antibacterial activity in vitro
against two bacterial isolates (E. coli NC101 and E. faecalis OGIRF) derived from
the mammalian gut (Fig. 5). Olanzapine undergoes enterohepatic recycling, and
an autopsy report found that olanzapine was concentrated by one to two orders of
magnitude in bile relative to the blood [54]. Local concentrations along the gut
lumen – from the duodenum to the distal colon – may thus far exceed steady-state
plasma levels. Although the microbial ecology of the gut is far too complex to
allow robust predictions from experiments with two bacterial strains tested in
isolation, our data supply proof of principle for the idea that olanzapine may
directly perturb the luminal enteric community. The EC50 metric is suited to
attempts to eradicate microbial pathogens; we hypothesize that therapeutic doses
of olanzapine, while well below estimated EC50, still provide a subtle selective
pressure that nudges the ecology of the gut towards an obesogenic composition.
Indeed, other antipsychotic drugs and their metabolites have antimicrobial
activity in vitro: for instance, chlorpromazine against Mycobacterium tuberculosis
[55] and thioridazine against a methicillin-resistant Staphylococcus aureus isolate
[56].
Germ-free animals provide a means for establishing causality in microbiome
studies. The absence of excess weight gain with olanzapine administration under
germ-free conditions demonstrates that the gut microbiota are required for this
drug effect. The rapid appearance of a weight gap in the olanzapine-treated group
following inoculation of all mice with cecal contents from a single donor
demonstrates that the gut microbiota are sufficient for the drug effect. Complex
bidirectional interactions occur between the brain, endocrine system, enteric
nervous system, gut epithelium and microbiota in both rodents and humans [57],
and olanzapine may perturb this ‘‘brain-gut-enteric microbiota’’ axis.
Nonetheless, whether the causal pathway is direct or indirect, the enteric
microbiota must mediate the effects of olanzapine on body weight.
In light of evidence that olanzapine has intrinsic antimicrobial activity, we
propose that its actions in the gut may be analogous to the chronic low-dose
antibiotic regimens used to promote weight gain in livestock. Such treatments
have been shown to shape the composition and the metabolic capacity of the gut
microbiota in mice, resulting in long-term changes in energy balance [23]. We
suggest that olanzapine may promote weight gain and adiposity by a similar
mechanism, and that inter-individual variability in composition of the gut
microbiota underlies variability in susceptibility to weight gain in human patients.
Furthermore, there is no reason to believe that olanzapine is unique in this
respect: weight gain is a common adverse effect of numerous drugs [58], many of
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which undergo enterohepatic circulation. The gut microbiota represents both a
biomarker and potential therapeutic target for drug-induced weight gain.
Supporting Information
S1 Figure. Survey of effects of orally-administered olanzapine (OLZ) on eight
inbred mouse strains. (A) Weight gain during 80 days of OLZ treatment versus
placebo in female mice from eight inbred laboratory strains (n54 OLZ-treated
and 4 placebo-treated mice per panel). OLZ was compounded into mouse feed at
50 mg/kg, and all mice were fed a high-fat diet ad libitum. (B) Plasma OLZ levels
after 18 weeks of treatment, by strain.
doi:10.1371/journal.pone.0115225.s001 (EPS)
S2 Figure. Dose titration for oral administration of olanzapine in female
C57BL/6J mice. (A) Plasma olanzapine (OLZ) concentration measured by LC-
MS/MS (49) vs. concentration in mouse food (n55 subjects). Grey shaded region
indicates target dose in human patients. (B) Dose-response relationship for OLZ
and two metabolic parameters, body weight (in grams) and adiposity (fat mass as
percentage of total body weight). Points indicate rate of increase per day in each
metabolic parameter, estimated by ordinary least-squares regression. Vertical bars
represent 95% confidence intervals (obtained by likelihood profiling) for the
drug-effect estimates.
doi:10.1371/journal.pone.0115225.s002 (EPS)
S3 Figure. Effects of olanzapine (OLZ) treatment on weight gain and adiposity.
(A) Weight gain over 9 weeks in female C57BL/6J mice fed a high-fat diet (HFD)
ad libitum. Each line represents a single mouse (n524 subjects); mice were 6
weeks of age at initiation of HFD. Grey shaded intervals indicate period of OLZ
treatment. (B) Adiposity (percent body fat) during HFD-OLZ versus HFD-
placebo phase at matched time points (n548 or 2 observations 624 subjects). (C)
Adiposity (percent body fat) versus body weight during HFD-placebo (open
circles) or HFD-OLZ (filled circles) phase. Pearson’s r50.819 (95% CI 0.697–
0.895) on n572 (3 observations 624 subjects).
doi:10.1371/journal.pone.0115225.s003 (EPS)
S4 Figure. Inter-individual variability in effect of olanzapine (OLZ) on weight
gain (n524 subjects). At left, confidence intervals for posterior mode of subject-
specific offset (eg. baseline weight differences); at right, confidence intervals for
subject-specific OLZ effect, which represent deviations from the overall mean
OLZ effect.
doi:10.1371/journal.pone.0115225.s004 (EPS)
S5 Figure. Between-subjects (b) diversity by unweighted UniFrac (n595
samples 54 time points 624 subjects – 1 failed sample), visualized using non-
metric multidimensional scaling. Panels are split by study arm (see Fig. 1C) and
observations on the same subject are connected by a grey line.
doi:10.1371/journal.pone.0115225.s005 (EPS)
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S6 Figure. Time series of gut microbiota composition at the individual level.
Colored regions show relative abundance, per subject, of specific bacterial classes
at each of the experiment’s four time points (see Fig. 1C). Subjects are grouped by
study arm (left, A; right, B) and cage (numbered sequentially, 1–6) as indicated in
the bar above each panel.
doi:10.1371/journal.pone.0115225.s006 (EPS)
S7 Figure. Rarefaction curves for assessing coverage of 16S rRNA sequencing.
Each curve plots the number of OTUs discovered (species richness; y-axis) as a
function of sequencing depth (reads per sample; x-axis) in a single sample (n595
samples 54 time points 624 subjects – 1 failed sample). Curves are grouped by
feces-collection time point (see Fig. 1C) and treatment status.
doi:10.1371/journal.pone.0115225.s007 (EPS)
S8 Figure. Maximum-likelihood phylogeny of operational taxonomic units
(OTUs) identified by 16S rDNA sequencing, unrooted (n58067 OTUs). Scale
for branch lengths is indicated by scale bar at lower-right, in units of nucleotide
substitutions per site.
doi:10.1371/journal.pone.0115225.s008 (EPS)
S9 Figure. Heatmap of (Pearson’s r) correlation matrix for 500 most-variable
OTUs, colored from blue (r5+1) through white (r50) to red (r521). Rows
and columns are hierarchically clustered in order to reveal block structure.
doi:10.1371/journal.pone.0115225.s009 (PNG)
S1 Table. Sample metadata for 96 fecal samples. Timepoints are coded in order
according to Fig. 1C.
doi:10.1371/journal.pone.0115225.s010 (XLSX)
S2 Table. Raw operational taxonomic unit (OTU) abundance table. Sample
identifiers follow those in S1 Table.
doi:10.1371/journal.pone.0115225.s011 (XLSX)
S3 Table. Taxonomic identification of operational taxonomic units (OTUs) to
the rank of family. Missing data are coded as ‘‘NA.’’ OTU identifiers follow those
in S2 Table.
doi:10.1371/journal.pone.0115225.s012 (XLSX)
S4 Table. Coefficient estimates for effect of olanzapine and high-fat diet on
abundance of specific operational taxonomic units (OTUs). OTU identifiers
follow those in S2 Table. Columns are as follows: Beta, the estimated effect on the
log scale (see S1 Notes); 95% CI, confidence bounds for the effect at nominal
significance level a50.05; Term, the effect being tested (drug or diet); p-value,
nominal p-value from likelihood-ratio test of null hypothesis that the true effect is
zero; FDR-adjusted p-value, nominal p-value adjusted for multiple-testing by the
method of Benjamini and Hochberg.
doi:10.1371/journal.pone.0115225.s013 (XLSX)
S1 Notes. Details of bioinformatics analyses and statistical methods.
doi:10.1371/journal.pone.0115225.s014 (DOCX)
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49. McCafferty J, Mühlbauer M, Gharaibeh RZ, Arthur JC, Perez-Chanona E, et al. (2013) Stochastic
changes over time and not founder effects drive cage effects in microbial community assembly in a
mouse model. ISME J 7: 2116–2125. doi:10.1038/ismej.2013.106.
50. Lozupone CA, Stombaugh J, Gonzalez A, Ackermann G, Wendel D, et al. (2013) Meta-analyses of
studies of the human microbiota. Genome Res 23: 1704–1714. doi:10.1101/gr.151803.112.
An Antipsychotic Drug Interacts with Gut Microbiome
PLOS ONE | DOI:10.1371/journal.pone.0115225 December 15, 2014 19 / 20
51. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, et al. (2011) Association between
composition of the human gastrointestinal microbiome and development of fatty liver with choline
deficiency. Gastroenterology 140: 976–986. doi:10.1053/j.gastro.2010.11.049.
52. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, et al. (2013) Fecal microbiome and volatile
organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin
Gastroenterol Hepatol 11: 868–75.e1–3. doi:10.1016/j.cgh.2013.02.015.
53. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. (2012) Inflammasome-mediated dysbiosis
regulates progression of NAFLD and obesity. Nature 482: 179–185. doi:10.1038/nature10809.
54. Jenkins AJ, Sarconi KM, Raaf HN (1998) Determination of olanzapine in a postmortem case. J Anal
Toxicol 22: 605–609.
55. Kristiansen JE (1979) Experiments to illustrate the effect of chlorpromazine on the permeability of the
bacterial cell wall. Acta Pathol Microbiol Scand B 87: 317–319.
56. Thorsing M, Klitgaard JK, Atilano ML, Skov MN, Kolmos HJ, et al. (2013) Thioridazine induces major
changes in global gene expression and cell wall composition in methicillin-resistant Staphylococcus
aureus USA300. PLoS One 8: e64518. doi:10.1371/journal.pone.0064518.
57. Rhee SH, Pothoulakis C, Mayer EA (2009) Principles and clinical implications of the brain-gut-enteric
microbiota axis. Nat Rev Gastroenterol Hepatol 6: 306–314. doi:10.1038/nrgastro.2009.35.
58. Leslie WS, Hankey CR, Lean MEJ (2007) Weight gain as an adverse effect of some commonly
prescribed drugs: a systematic review. QJM 100: 395–404. doi:10.1093/qjmed/hcm044.
An Antipsychotic Drug Interacts with Gut Microbiome
PLOS ONE | DOI:10.1371/journal.pone.0115225 December 15, 2014 20 / 20
